Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
20 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Eiger BioPharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Eiger BioPharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Eiger BioPharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Eiger BioPharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Eiger BioPharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Eiger BioPharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Eiger BioPharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Eiger BioPharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Eiger BioPharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eiger BioPharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Eiger BioPharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Eiger BioPharmaceuticals, Inc. Snapshot 4 Eiger BioPharmaceuticals, Inc. Overview 4 Key Information 4 Key Facts 4 Eiger BioPharmaceuticals, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Eiger BioPharmaceuticals, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Eiger BioPharmaceuticals, Inc. - Pipeline Products Glance 9 Eiger BioPharmaceuticals, Inc. - Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Eiger BioPharmaceuticals, Inc. - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Eiger BioPharmaceuticals, Inc. - Drug Profiles 11 EBP-921 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 lonafarnib 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 EBP-1597 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Eiger BioPharmaceuticals, Inc. - Pipeline Analysis 14 Eiger BioPharmaceuticals, Inc. - Pipeline Products by Target 14 Eiger BioPharmaceuticals, Inc. - Pipeline Products by Molecule Type 15 Eiger BioPharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 16 Eiger BioPharmaceuticals, Inc. - Dormant Projects 17 Eiger BioPharmaceuticals, Inc. - Locations And Subsidiaries 18 Head Office 18 Appendix 19 Methodology 19 Coverage 19 Secondary Research 19 Primary Research 19 Expert Panel Validation 19 Contact Us 20 Disclaimer 20
List of Tables Eiger BioPharmaceuticals, Inc., Key Information 4 Eiger BioPharmaceuticals, Inc., Key Facts 4 Eiger BioPharmaceuticals, Inc. - Pipeline by Indication, 2014 6 Eiger BioPharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 7 Eiger BioPharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 8 Eiger BioPharmaceuticals, Inc. - Phase II, 2014 9 Eiger BioPharmaceuticals, Inc. - Preclinical, 2014 10 Eiger BioPharmaceuticals, Inc. - Pipeline by Target, 2014 14 Eiger BioPharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 15 Eiger BioPharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 16 Eiger BioPharmaceuticals, Inc. - Dormant Developmental Projects,2014 17
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.